Abiopharma

🔍 Flammer Martina M.D. (Executive)

Company: INSMED Inc (INSM)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 5,998 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 89,109.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 5,645 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 94,754.00 | transaction_form_type: 4 | Footnotes: F3, F2
• Acquired 4,358 shares of Common Stock at $19.74 per share (Direct)
  Date: 2026-01-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 99,112.00 | transaction_form_type: 4 | Footnotes: F4
• Acquired 7,945 shares of Common Stock at $29.13 per share (Direct)
  Date: 2026-01-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 107,057.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 2,799 shares of Common Stock at $169.29 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 104,258.00 | transaction_form_type: 4 | Footnotes: F4, F5
• Sold 3,205 shares of Common Stock at $170.61 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 101,053.00 | transaction_form_type: 4 | Footnotes: F4, F6
• Sold 2,836 shares of Common Stock at $171.19 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 98,217.00 | transaction_form_type: 4 | Footnotes: F4, F7
• Sold 286 shares of Common Stock at $171.92 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 97,931.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 1,820 shares of Common Stock at $173.45 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 96,111.00 | transaction_form_type: 4 | Footnotes: F4, F8
• Sold 655 shares of Common Stock at $174.28 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 95,456.00 | transaction_form_type: 4 | Footnotes: F4, F9
• Sold 702 shares of Common Stock at $175.73 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 94,754.00 | transaction_form_type: 4 | Footnotes: F4, F10
• Acquired 31,280 shares of Stock Option (right to buy) at $177.12 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-02 | equity_swap_involved: 0 | shares_owned_after: 31,280.00 | transaction_form_type: 4 | Footnotes: F11
• Sold 4,358 shares of Stock Option (right to buy) at $19.74 per share (Derivative)
  Date: 2026-01-05 | Code: M | Expires: 2033-01-05 | equity_swap_involved: 0 | shares_owned_after: 8,715.00 | transaction_form_type: 4 | Footnotes: F4, F12
• Sold 7,945 shares of Stock Option (right to buy) at $29.13 per share (Derivative)
  Date: 2026-01-05 | Code: M | Expires: 2034-01-04 | equity_swap_involved: 0 | shares_owned_after: 31,780.00 | transaction_form_type: 4 | Footnotes: F4, F12

Footnotes:

• F1: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested.
• F2: Each RSU was granted on January 2, 2026 for no consideration.
• F3: Represents RSUs, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest in full on February 1, 2029.
• F4: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
• F5: This is the weighted average sales price representing 2,799 shares sold at prices ranging from $168.88 to $169.69 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
• F6: This is the weighted average sales price representing 3,205 shares sold at prices ranging from $169.91 to $170.90 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
• F7: This is the weighted average sales price representing 2,836 shares sold at prices ranging from $170.91 to $171.89 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
• F8: This is the weighted average sales price representing 1,820 shares sold at prices ranging from $173.05 to $173.87 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
• F9: This is the weighted average sales price representing 655 shares sold at prices ranging from $174.20 to $174.43 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
• F10: This is the weighted average sales price representing 702 shares sold at prices ranging from $175.54 to $176.12 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
• F11: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.
• F12: The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.